Courtagen, Astellas Collaborate

Courtagen enters data partnership with Astellas for early stage therapeutic development program to address mitochondrial disease. 

Courtagen Life Sciences, Inc. announced collaboration with Astellas Pharma Inc. Courtagen will utilize its molecular information platform to aid in the development of a predictive model to support early stage therapeutic development for mitochondrial disease. 

“Astellas and Courtagen share a commitment to innovative clinical solutions that address the needs of patients suffering from mitochondrial based disorders.” states Brian McKernan, Chief Executive Officer of Courtagen. “Courtagen was founded on the idea of helping patients suffering from mitochondrial disorders, and now we are able to utilize our unique capability to correlate clinical data with specific genomic alterations and aid in the development of targeted therapeutics.”